IGN-311. Igeneon.
Igeneon, under license from Protein Design Labs, is developing IGN-311, an intravenous humanized monoclonal antibody against the Lewis Y carbohydrate antigen, as a potential agent for the passive immunotherapy of cancer, particularly epithelial tumors affecting breast, colon, gastric and pancreatic tissues. A phase I/II trial of IGN-311 was initiated in July 2005.
Kristeleit
Hartmut
H
Institute of Cancer Research, The Breakthrough Toby Robins Breast Cancer Research Center, 237 Fulham Road, London SW3 6JB, UK. Hartmut.Kristeleit@icr.ac.uk
D000818:Animals; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D007983:Lewis Blood Group Antigens / Q000276:immunology*; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C510956:IGN 311; D007983:Lewis Blood Group Antigens; C094162:Lewis Y antigen; D066246:ErbB Receptors